Sign in
What Happens to Diabetic Retinopathy Severity Scores With Less Aggressive Treatment? A Post Hoc Analysis of the RISE and RIDE Open Label Extension Study
Roger A. Goldberg, MD, MBA
Updates from the Field
2019
Differences in Intravitreal Silicone Oil Following Multiple Bevacizumab, Ranibizumab, and Aflibercept Injections
John T. Thompson, MD
Annual Meeting Talks
Potential Safety Concerns of Bevacizumab
Robert L. Avery, MD
2017
Category: Diabetic Retinopathy